0001144204-19-018975.txt : 20190510 0001144204-19-018975.hdr.sgml : 20190510 20190410070016 ACCESSION NUMBER: 0001144204-19-018975 CONFORMED SUBMISSION TYPE: CORRESP PUBLIC DOCUMENT COUNT: 2 FILED AS OF DATE: 20190410 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Protalix BioTherapeutics, Inc. CENTRAL INDEX KEY: 0001006281 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 650643773 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: CORRESP BUSINESS ADDRESS: STREET 1: 2 SNUNIT ST STREET 2: SCIENCE PARK, POB 455 CITY: CARMIEL STATE: L3 ZIP: 20100 BUSINESS PHONE: 972-4-988-9488 MAIL ADDRESS: STREET 1: 2 SNUNIT ST STREET 2: SCIENCE PARK, POB 455 CITY: CARMIEL STATE: L3 ZIP: 20100 FORMER COMPANY: FORMER CONFORMED NAME: ORTHODONTIX INC DATE OF NAME CHANGE: 19980422 FORMER COMPANY: FORMER CONFORMED NAME: EMBASSY ACQUISITION CORP DATE OF NAME CHANGE: 19960124 CORRESP 1 filename1.htm

 

 

 

April 10, 2019

 

VIA EDGAR

Joseph McCann

Office of Healthcare and Insurance

U.S. Securities and Exchange Commission

Division of Corporate Finance

Mail Stop 4720

100 F Street, N.E.

Washington, D.C. 20549

 

Re:Protalix BioTherapeutics, Inc.
Registration Statement on Form S-3

Filed March 29, 2019
File No. 333-230604

 

Dear Mr. McCann:

 

We refer to the registration statement on Form S-3 (File No. 333-230604) (the “Registration Statement”) of Protalix BioTherapeutics, Inc., a Delaware corporation (the “Company”). In accordance with Rule 461 under the Securities Act of 1933, as amended, the Company hereby respectfully requests the acceleration of the effectiveness of the Registration Statement so that it may become effective at 4:05 p.m. (Eastern time) on April 12, 2019 or as soon as practicable thereafter.

 

We thank you in advance for your time and attention to the Registration Statement. Should you wish to discuss the enclosed materials at any time, please do not hesitate to contact me at +972 (4) 902-8100 or YossiM@protalix.com, or the Company’s counsel, Anna T. Pinedo of Mayer Brown LLP at +1 (212) 506-2275 or apinedo@mayerbrown.com.

 

Sincerely,

 

/s/ Yossi Maimon

Yossi Maimon
Vice President and Chief Financial Officer
Protalix BioTherapeutics, Inc.

 

cc:Moshe Manor

Protalix BioTherapeutics, Inc.

 

Anna T. Pinedo
Mayer Brown LLP

 

 

 

2 Snunit Street, Science Park P.O.B. 455, Carmiel 20100, Israel

Tel: 972-4-988-9488 | Fax: 972-4-988-9489 | Web: www.protalix.com

 

 

 

GRAPHIC 2 image_001.jpg GRAPHIC begin 644 image_001.jpg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